Healthcare
Rocket Pharmaceuticals, Inc.(RCKT)
Live Price
Offline$3.35
+6.01% today
1Y Change
+0.76%
Window
Jun 23, 2025 β Jun 9, 2026
- Market Cap
- $390.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +26.4%
- Dividend Yield
- 0.0%
Coverage: 242 bars Β· Jun 23, 2025 β Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rocket Pharmaceuticals, Inc. (RCKT) is a Healthcare stock with a market cap of $390.00M and listed on NASDAQ. The stock last traded around $3.35 and up 0.8% across the available one-year price window (Jun 23, 2025 β Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.4%, free cash flow +11.7% with operating margin 0.0% and ROIC -76.4%. Stock Foundry combines RCKT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +26.4%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | β | -4.4% | -8.5% | β |
2026 Feb 26, 2026 | +9.5% | +10.6% | +2.4% | +3.5% |
2025 Nov 6, 2025 | +6.3% | -1.9% | -1.9% | +2.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCKT
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RCKT Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RCKT and SPY.
Company Overview
Rocket Pharmaceuticals, Inc.
NASDAQ Global Market
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones EnergΓ©ticas, Medioambientales y TecnolΓ³gicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
- Leadership
- Gaurav D. Shah
- IPO Date
- Feb 18, 2015
- Employees
- 299
- Street Address
- 9 Cedarbrook Drive
- Mailing
- Cranbury, NJ, 08512
- Region
- Cranbury, NJ, US
- Reporting Currency
- USD
- Investor Line
- 609 659 8001
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 1.4
Growth
- Revenue
- 0.0%
- EPS
- +26.4%
- Free Cash Flow
- +11.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -65.8%
- ROIC
- -76.4%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 6.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.